| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Jan 10, 2025 | Jan 14, 2025 | Generation Bio Co. | Director | Buy | 95.0 | +210,791 | 238.20% | ✗ | $203.2K |
| Dec 1, 2023 | Dec 5, 2023 | Generation Bio Co. | Director | Buy | 95.0 | +88,495 | 121.50% | ✗ | $124.8K |
| Mar 16, 2022 | Mar 18, 2022 | Spyre Therapeutics, Inc. | CEO | Buy | 95.0 | +80,079 | 10.87% | ✗ | $187.7K |
| Mar 11, 2022 | Mar 15, 2022 | Spyre Therapeutics, Inc. | CEO | Buy | 97.5 | +144,666 | 24.31% | ✗ | $280.9K |
| Dec 9, 2021 | Dec 13, 2021 | Spyre Therapeutics, Inc. | CEO | Buy | 90.0 | +53,634 | 9.91% | ✗ | $199K |
| Apr 30, 2020 | May 4, 2020 | Spyre Therapeutics, Inc. | CEO | Buy | 97.5 | +165,000 | 44.18% | ✗ | $783.8K |
| Jun 12, 2019 | Jun 14, 2019 | Spyre Therapeutics, Inc. | CEO | Buy | 90.0 | +31,905 | 9.92% | ✗ | $196.5K |
| May 20, 2019 | May 22, 2019 | Spyre Therapeutics, Inc. | CEO | Buy | 90.0 | +26,592 | 9.01% | ✗ | $180K |
| Feb 15, 2019 | May 17, 2019 | Spyre Therapeutics, Inc. | CEO | Buy | 90.0 | +18,713 | 6.77% | ✗ | $126.4K |
| Feb 15, 2018 | Dec 10, 2018 | Spyre Therapeutics, Inc. | CEO | Buy | 83.8 | +2,994 | 3.23% | ✗ | $21.1K |
| Dec 6, 2017 | Dec 8, 2017 | Spyre Therapeutics, Inc. | CEO | Buy | 91.3 | +8,288 | 30.56% | ✗ | $41.1K |
| Dec 1, 2017 | Dec 5, 2017 | Spyre Therapeutics, Inc. | Director | Buy | 95.0 | +17,121 | 171.21% | ✗ | $83.2K |
| Apr 12, 2016 | Apr 12, 2016 | Spyre Therapeutics, Inc. | Director | Buy | 95.0 | +10,000 | 100.00% | ✗ | $100K |